Adam Mostafa - X4 Pharmaceuticals CFO, Treasurer, Assistant Secretary
| XFOR Stock | USD 0.30 0.0004 0.13% |
CFO
Mr. Adam S. Mostafa is Chief Financial Officer, Treasurer, Assistant Secretary of the Company. He has served as X4s Chief Financial Officer since September 2018. Prior to joining X4, Mr. Mostafa served as chief financial officer of Abpro Corporationrationration, a biotechnology company focused on antibody therapeutics, from June 2016 to August 2018. Prior to that, Mr. Mostafa was a managing director in the healthcare investment banking group at Cantor Fitzgerald from January 2015 to May 2016, and from June 2011 to January 2015, Mr. Mostafa was a senior banker in the healthcare investment banking group at Needham Company. Prior to that, Mr. Mostafa was a vice president in the investment banking group at CRT Capital Group from March 2007 to May 2011, and from September 2003 to March 2007, Mr. Mostafa was a portfolio management associate in the global stock selection group at AQR Capital. Mr. Mostafa began his career as an analyst in the healthcare investment banking group at Salomon Smith Barney. Mr. Mostafa earned an A.B. in Economics from Brown University. since 2019.
| Age | 44 |
| Tenure | 6 years |
| Address | 61 North Beacon Street, Boston, MA, United States, 02134 |
| Phone | 857 529 8300 |
| Web | https://www.x4pharma.com |
Adam Mostafa Latest Insider Activity
Tracking and analyzing the buying and selling activities of Adam Mostafa against X4 Pharmaceuticals stock is an integral part of due diligence when investing in X4 Pharmaceuticals. Adam Mostafa insider activity provides valuable insight into whether X4 Pharmaceuticals is net buyers or sellers over its current business cycle. Note, X4 Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell X4 Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Adam Mostafa over six months ago Disposition of 10834 shares by Adam Mostafa of X4 Pharmaceuticals subject to Rule 16b-3 |
X4 Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4655) % which means that it has lost $0.4655 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2635) %, meaning that it created substantial loss on money invested by shareholders. X4 Pharmaceuticals' management efficiency ratios could be used to measure how well X4 Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 03/21/2025, Return On Tangible Assets is likely to drop to -0.74. In addition to that, Return On Capital Employed is likely to drop to -1.04. At this time, X4 Pharmaceuticals' Other Current Assets are relatively stable compared to the past year. As of 03/21/2025, Net Tangible Assets is likely to grow to about 68.5 M, while Non Current Assets Total are likely to drop slightly above 19.2 M.Similar Executives
| Found 3 records | CFO Age | ||
| Matt Zuga | Acumen Pharmaceuticals | N/A | |
| Mary MBA | Hookipa Pharma | 62 | |
| PMP CPA | Elevation Oncology | 54 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.47 |
X4 Pharmaceuticals Leadership Team
Elected by the shareholders, the X4 Pharmaceuticals' board of directors comprises two types of representatives: X4 Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of XFOR. The board's role is to monitor X4 Pharmaceuticals' management team and ensure that shareholders' interests are well served. X4 Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, X4 Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert Arbeit, Senior Research | ||
| Mary DiBiase, Chief Officer | ||
| Paula Ragan, President CEO, Secretary, Director | ||
| Keith MD, Founder Board | ||
| Pharm MPH, Vice Communications | ||
| Adam Mostafa, CFO, Treasurer, Assistant Secretary | ||
| Renato Skerlj, Founder | ||
| Arthur Taveras, Chief Officer | ||
| Murray MD, Interim Director | ||
| Mark MBA, Chief Officer | ||
| Richard MD, Chairman Founder | ||
| MBA MD, Chief Officer |
XFOR Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is X4 Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.47 | ||||
| Operating Margin | (61.61) % | ||||
| Current Valuation | (5.68 M) | ||||
| Shares Outstanding | 170.55 M | ||||
| Shares Owned By Insiders | 1.27 % | ||||
| Shares Owned By Institutions | 59.19 % | ||||
| Number Of Shares Shorted | 11.06 M | ||||
| Price To Book | 0.86 X | ||||
| Price To Sales | 45.50 X |
Pair Trading with X4 Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with XFOR Stock
Moving against XFOR Stock
| 0.75 | CMRX | Chimerix Sell-off Trend | PairCorr |
| 0.74 | CPIX | Cumberland Pharmaceuticals | PairCorr |
| 0.64 | FNA | Paragon 28 | PairCorr |
The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.
The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for XFOR Stock Analysis
When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.